Investigation Launched Into Veracyte as Shareholders Face Major Losses
On November 4, 2026, Veracyte, a publicly traded company under the NASDAQ symbol VCYT, reported disappointing figures for its Decipher Prostate test, which led to a steep decline in the stock price. Investors watching the stock were disheartened as shares plummeted by over 50% in response to the news. This dramatic drop has prompted the law firm Levi & Korsinsky to step in, announcing a pending investigation into the potential violations of securities laws by the company.
The situation unfolded following the third-quarter earnings report, where Veracyte revealed that the volume for Decipher Prostate tests fell significantly short of management's expectations. Previously, the company had projected a testing volume of approximately 20,000 tests annually with a margin of 1,000 tests. However, this forecast was dramatically revised downward, now estimating the test volume to be between 12,000 and 15,000 tests for the year.
As if this wasn’t enough to unsettle investors, Veracyte also reduced its financial projections. The revenue expectations were revised downwards with total revenue for 2026 now estimated to be between $590 million to $593 million, a notable decrease of $3 million from the earlier estimates. Specifically for testing revenues, previously projected between $576 million and $582 million, the company now expects only around $572 million.
In light of these developments, Levi & Korsinsky has initiated an investigation into whether Veracyte's earlier statements regarding the growth outlook for its Decipher Prostate test were misleading. Investors who held VCYT during this downturn and have incurred financial losses may have legal rights and are encouraged to reach out for a free confidential loss assessment.
The law firm is particularly notable for being ranked among the top 50 in ISS Securities Class Action Services for several consecutive years, establishing itself as a significant player in shareholder rights litigation. Their team, consisting of over 70 professionals, has successfully recovered billions of dollars for investors in past legal actions.
For those interested in participating in this investigation, it is essential to understand the eligibility requirements. Investors who purchased VCYT stock and experienced any financial loss may qualify. It is important to note that eligibility is based on the purchase date and documented losses rather than current holdings in the stock.
Moreover, participants in the investigation do not need to go to court or provide testimonies, making it a low-friction opportunity for investors seeking to understand their legal options. Details regarding brokerage records and trade confirmations will be necessary for those looking to establish their claims. Even if VCYT shares have been sold, losses incurred during the investment period can still be pursued in this action.
As the investigation unfolds, those affected are encouraged to gather their brokerage statements, which document their purchase dates, share quantities, and the prices paid, to begin the process of potential recovery. Veracyte's announcement could have far-reaching implications, not just for the company but also for its shareholders who may feel blindsided by these sudden changes in growth and revenue expectations.
For further assistance, stakeholders can contact Joseph E. Levi, Esq., through email or phone provided in the original press release from Levi & Korsinsky. The uncertainty surrounding Veracyte’s future and the upcoming legal landscape will be closely watched by both investors and industry analysts alike. As these developments progress, shareholders must stay informed about their rights and potential actions available to them in this tumultuous time in the market.
This investigation into Veracyte highlights the importance of transparency and accountability in corporate communications—the outcomes of which could impact investor trust and future stock performance. The full ramifications of the recent earnings report and the investigation by Levi & Korsinsky will become clearer in the coming weeks, making it a critical moment for VCYT investors.
The situation unfolded following the third-quarter earnings report, where Veracyte revealed that the volume for Decipher Prostate tests fell significantly short of management's expectations. Previously, the company had projected a testing volume of approximately 20,000 tests annually with a margin of 1,000 tests. However, this forecast was dramatically revised downward, now estimating the test volume to be between 12,000 and 15,000 tests for the year.
As if this wasn’t enough to unsettle investors, Veracyte also reduced its financial projections. The revenue expectations were revised downwards with total revenue for 2026 now estimated to be between $590 million to $593 million, a notable decrease of $3 million from the earlier estimates. Specifically for testing revenues, previously projected between $576 million and $582 million, the company now expects only around $572 million.
In light of these developments, Levi & Korsinsky has initiated an investigation into whether Veracyte's earlier statements regarding the growth outlook for its Decipher Prostate test were misleading. Investors who held VCYT during this downturn and have incurred financial losses may have legal rights and are encouraged to reach out for a free confidential loss assessment.
The law firm is particularly notable for being ranked among the top 50 in ISS Securities Class Action Services for several consecutive years, establishing itself as a significant player in shareholder rights litigation. Their team, consisting of over 70 professionals, has successfully recovered billions of dollars for investors in past legal actions.
For those interested in participating in this investigation, it is essential to understand the eligibility requirements. Investors who purchased VCYT stock and experienced any financial loss may qualify. It is important to note that eligibility is based on the purchase date and documented losses rather than current holdings in the stock.
Moreover, participants in the investigation do not need to go to court or provide testimonies, making it a low-friction opportunity for investors seeking to understand their legal options. Details regarding brokerage records and trade confirmations will be necessary for those looking to establish their claims. Even if VCYT shares have been sold, losses incurred during the investment period can still be pursued in this action.
As the investigation unfolds, those affected are encouraged to gather their brokerage statements, which document their purchase dates, share quantities, and the prices paid, to begin the process of potential recovery. Veracyte's announcement could have far-reaching implications, not just for the company but also for its shareholders who may feel blindsided by these sudden changes in growth and revenue expectations.
For further assistance, stakeholders can contact Joseph E. Levi, Esq., through email or phone provided in the original press release from Levi & Korsinsky. The uncertainty surrounding Veracyte’s future and the upcoming legal landscape will be closely watched by both investors and industry analysts alike. As these developments progress, shareholders must stay informed about their rights and potential actions available to them in this tumultuous time in the market.
This investigation into Veracyte highlights the importance of transparency and accountability in corporate communications—the outcomes of which could impact investor trust and future stock performance. The full ramifications of the recent earnings report and the investigation by Levi & Korsinsky will become clearer in the coming weeks, making it a critical moment for VCYT investors.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.